Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)
Conditions
Esophageal Cancer - Adenocarcinoma
Conditions: official terms
Adenocarcinoma - Esophageal Neoplasms
Conditions: Keywords
esophagectomy, endoscopy, biopsy, Tissue mesothelin, Serum mesothelin, 11-037
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Intervention
Name: serum and tissue mesothelin Type: Other
Name: serum and tissue mesothelin Type: Other
Name: serum and tissue mesothelin Type: Other
Overall Status
Recruiting
Summary
The purpose of this study is to find out whether a protein, called mesothelin, found in the blood and tissue can be used as "marker" for esophageal cancer. Doctors at Memorial Sloan-Kettering Cancer Center would like to compare levels of this protein in patients with abnormal cells or tissue of the esophageal to the levels of this protein in patients being treated for cancer for the esophagus.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients with T1 adenocarcinoma or suspected adenocarcinoma who are scheduled for a biopsy and mucosal resection (Group 1)

- Patients with a T1-2N0 adenocarcinoma or suspected adenocarcinoma who are scheduled to undergo and esophagectomy (Group 2)

- Patients with T2N1 and T3N0-1 adenocarcinoma or suspected adenocarcinoma who are scheduled to undergo endoscopy and biopsy and/or endoscopic ultrasound and biopsy prior to pre-operative chemo-radiotherapy and have baseline and surgical tissue available for staining (Group 3)

Exclusion Criteria:

- Patients <18 years of age

- Patients unfit medically for endoscopy surveillance and therapy

- Patients unfit medically for esophagectomy

- Patients with stage IV esophageal adenocarcinoma

- Patients previously treated with chemo-radiotherapy for their esophageal cancer

- Patients with squamous cell carcinoma of the esophagus

- Patients who have a history of cancer within 3 years or have a concurrent cancer.
Location
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Status: Recruiting
Contact: Nabil Rizk, MD - 212-639-8357
Start Date
March 2011
Completion Date
March 2016
Sponsors
Memorial Sloan Kettering Cancer Center
Source
Memorial Sloan Kettering Cancer Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page